##  [Freyr to offer Strategic Regulatory Services to a Global 700+ million Biopharma Company](/press-releases/freyr-to-offer-strategic-regulatory-services-to-a-global-700-million-biopharma-company) 

 ![Freyr to offer Strategic Regulatory Services to a Global 700+ million Biopharma Company](/sites/default/files/press-release-thumbnials/Freyr%20to%20offer%20Strategic%20Regulatory%20Services%20to%20a%20Global%20700%2B%20million%20Biopharma%20Company.webp)

Freyr has recently won a strategic Regulatory services project from a leading India-based, global 700+ million biopharmaceutical company. The project reiterates Freyr’s ever-growing global expertise in offering highly cost-effective, and technology-enabled Regulatory solutions and services.

As part of the offerings, Freyr aims to support its India-based Biopharma client with an [end-to-end regulatory strategy](https://www.freyrsolutions.com/outsourcing-services/regulatory-outsourcing-services) for New Chemical Entity (NCE) and Biosimilar products in the emerging LATAM markets like Brazil & Mexico within the short proposed timelines.

“Such niche and time-bound projects prove Freyr’s capability as an end-to-end Regulatory service provider in terms of meeting the complex demands of the global Regulatory landscape. Providing top-notch client service has always been our goal and we are happy to take the leap towards it with multi-geo assignments like this” said Rajiv Rangan, Co-CEO, Freyr.